Beijing Anzhen Hospital: China’s Global Leader in Cardiovascular Medicine
Share
About Beijing Anzhen Hospital
Established on April 14, 1984, Beijing Anzhen Hospital was founded under the vision of Academician Wu Yingkai, one of China’s most respected cardiac surgeons. As part of the Beijing Institute of Heart, Lung, and Vascular Diseases, the hospital quickly rose to national prominence, performing over 600 cardiac surgeries within three years of its founding and completing China’s second heart transplant only seven years later. These milestones established Anzhen as a national leader in cardiac medicine.
Over four decades of development, the hospital has evolved through several stages — from “strong specialty and focused integration” to “comprehensive excellence with world-class specialties.” Today, Anzhen stands as a global leader in cardiovascular diagnosis, treatment, and innovation.
Clinical Excellence
Beijing Anzhen Hospital is the National Clinical Research Center for Cardiovascular Diseases and serves as a National Regional Medical Center.
- For three consecutive years since 2021, both its Cardiology and Cardiac Surgery Departments have ranked No.1 in China in surgery volume and clinical outcomes.
- It performs tens of thousands of cardiovascular surgeries annually with world-class success rates, establishing itself as the “final stop for cardiovascular care” in China.
The hospital currently employs over 4,000 medical professionals, including 70+ national and provincial-level experts, Beijing Scholars, and National Science Fund for Distinguished Young Scholars recipients.
It has 1 national key discipline (Cardiology), 5 national key clinical specialties, and 7 provincial key specialties, supported by 2 Beijing Quality Control Centers for Cardiovascular Medicine and Extracorporeal Life Support.
Education and Research
As the Sixth Clinical Medical School of Capital Medical University, Anzhen Hospital is one of China’s top teaching hospitals in cardiovascular education.
- Doctoral programs: 18 disciplines with 88 PhD supervisors
- Master’s programs: 32 disciplines with 223 supervisors
- Ongoing students: over 1,900
- Training bases: 16 for standardized residency, 3 for specialized physician training
Over the decades, the hospital has trained tens of thousands of high-level cardiovascular specialists across the nation.
Anzhen is also home to five national research platforms and 17 provincial-level laboratories, including:
- Ministry of Education Key Laboratory for Cardiovascular Remodeling
- Biomedical Engineering Lab for Cardiovascular Diseases
- National Innovation Talent Development Base
Its large-scale disease databases — including the China Coronary Artery Disease Cohort and Atrial Fibrillation Registry — represent the largest cardiovascular patient cohorts in Asia, supporting precision medicine and big data research.
Expansion and Future Vision
The newly opened Tongzhou Campus, inaugurated in October 2024, marks a major milestone in Beijing’s healthcare development.
- Located in the city’s sub-center near Langfang, Hebei, the new campus covers 340,000 square meters with 1,300 beds.
- It provides integrated cardiovascular emergency and critical care services to the Beijing-Tianjin-Hebei region, expanding the hospital’s capacity and accessibility.
With Tongzhou and Chaoyang campuses operating under an integrated model, Anzhen Hospital is transitioning toward a research-driven, innovation-oriented medical system, striving to remain a world leader in cardiovascular medicine.
Conclusion
Beijing Anzhen Hospital represents the pinnacle of cardiovascular healthcare in China — blending clinical excellence, scientific innovation, and medical education. As one of the world’s largest heart centers, it continues to lead global cardiovascular care, delivering world-class outcomes for patients from China and beyond.